Dara Biosciences Inc (DARA) financial statements (2020 and earlier)

Company profile

Business Address 8601 SIX FORKS ROAD SUITE 160
RALEIGH, NC 27615
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1237
Cash and cash equivalents1236
Short-term investments  0
Receivables100
Inventory, net of allowances, customer advances and progress billings000
Inventory000
Prepaid expense and other current assets0
Other undisclosed current assets00 
Total current assets:1447
Noncurrent Assets
Property, plant and equipment000
Intangible assets, net (including goodwill)445
Goodwill111
Intangible assets, net (excluding goodwill)334
Restricted cash and investments000
Prepaid expense and other noncurrent assets0
Total noncurrent assets:445
TOTAL ASSETS:18812
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities222
Accounts payable011
Accrued liabilities110
Employee-related liabilities100
Debt000
Other undisclosed current liabilities100
Total current liabilities:422
Noncurrent Liabilities
Long-term debt and lease obligation000
Capital lease obligations000
Liabilities, other than long-term debt000
Deferred revenue and credits000
Other undisclosed noncurrent liabilities 11
Total noncurrent liabilities:011
Total liabilities:423
Stockholders' equity
Stockholders' equity attributable to parent, including:14710
Preferred stock  0
Common stock000
Additional paid in capital806356
Accumulated other comprehensive income  0
Accumulated deficit(66)(57)(47)
Other undisclosed stockholders' equity attributable to parent000
Stockholders' equity attributable to noncontrolling interest (1)(1)
Total stockholders' equity:1469
TOTAL LIABILITIES AND EQUITY:18812

Income statement (P&L) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Revenues200
Revenue, net  0
Cost of revenue
(Cost of Goods and Services Sold)
(1)(0)(0)
Gross profit:100
Operating expenses(11)(11)(10)
Other undisclosed operating income1  
Operating loss:(9)(10)(10)
Nonoperating income001
Other nonoperating income00 
Interest and debt expense (0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes  0
Loss from continuing operations before equity method investments, income taxes:(9)(10)(9)
Other undisclosed income from continuing operations before income taxes 0 
Loss from continuing operations before income taxes:(9)(10)(9)
Income tax expense (benefit) (0)1
Net loss:(9)(10)(8)
Net income attributable to noncontrolling interest000
Net loss available to common stockholders, diluted:(9)(10)(7)

Comprehensive Income ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Net loss:(9)(10)(8)
Other comprehensive income  0
Other undisclosed comprehensive income  8
Comprehensive income (loss):(9)(10)0
Comprehensive income (loss), net of tax, attributable to noncontrolling interest00(0)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 10(8)
Comprehensive loss, net of tax, attributable to parent:(9)(0)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: